NINDS Division of Translational Research HEAL Biomarker Webinar

Wed, 11/1/2023 - 3:30pm - 4:30pm

Overview

During this 1-hour virtual webinar, attendees will hear from the HEAL Biomarker Program Officials on the new Notice of Funding Opportunity (NOFO) "RFA-NS-24-023: HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3 - Clinical Trial Optional)." The goal of this event is to have an interactive webinar about the NOFO where attendees will have the opportunity to submit questions during the Q&A portion. All investigators interested in learning about the HEAL Biomarker funding opportunities are encouraged to participate.

Topics Covered

  • HEAL Biomarker Program Overview
  • Present new NOFO: RFA-NS-24-023: HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3 - Clinical Trial Optional)

Agenda

3:30 p.m. – 3:45 p.m.

Helping to End Addiction Long-term® Initiative Introduction and Overview
Speaker: Dr. Ram Arudchandran, Program Director, NIH HEAL Biomarker Program

3:45 p.m. – 4:15 p.m.

RFA-24-023 Overview
Speaker: Dr. Ram Arudchandran, Program Director, NIH HEAL Biomarker Program

4:15 p.m. – 4:30 p.m.

Q&A Session
Speaker: Dr. Ram Arudchandran, Program Director, NIH HEAL Biomarker Program

Speakers

Dr. Ram Arudchandran, Program Director, NIH HEAL Initiative Biomarker Program

Arudchandran joined the Division of Translational Research, National Institute of Neurological Disorders and Stroke, in May 2021 and currently serves as the Program Director for the HEAL Biomarker Program. He leads the HEAL Biomarker Program and is responsible for the HEAL Biomarker Program grant portfolio. Arudchandran previously served as Program Officer in the Office of Translational Initiatives and Program Innovations at the National Institute on Drug Abuse (NIDA), where he had a leading role in the new initiative, “Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research.” He was also responsible for coordination, management, and evaluation of NIDA Small Business Innovation Research/Small Business Technology Transfer Programs in the areas of Therapeutics Development and Biomarker Development and Validation.